Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Whole virion, inactivated, containing antigen*: A/Vietnam/1194/2004 (H5N1)* produced in eggs
GlaxoSmithKline Biologicals S.A.
J07BB01
pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Vaccines
Influenza, Human; Immunization; Disease Outbreaks
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
Withdrawn
2007-03-21
37 B. PACKAGE LEAFLET 38 PACKAGE LEAFLET: INFORMATION FOR THE USER DARONRIX, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Pandemic influenza vaccine (whole virion, inactivated, adjuvanted) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS VACCINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This vaccine has been prescribed for you. Do not pass it on to others. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET : 1. What Daronrix is and what it is used for 2. Before you receive Daronrix 3. How Daronrix is given 4. Possible side effects 5. How to store Daronrix 6. Further information 1. WHAT DARONRIX IS AND WHAT IT IS USED FOR Daronrix is a vaccine used in adults aged 18 to 60 years to prevent influenza (flu) in an officially declared pandemic. The vaccine works by causing the body to produce its own protection (antibodies) against the disease. Pandemic flu is a type of influenza that occurs every few decades and which spreads rapidly to affect most countries and regions around the world. The symptoms of pandemic flu are similar to those of “ordinary” flu but are usually more severe. 2. BEFORE YOU RECEIVE DARONRIX DARONRIX SHOULD NOT BE GIVEN: • if you have previously had any allergic reaction to Daronrix, or any ingredient (including eggs, chicken protein, gentamicin sulphate (antibiotic)) contained in this vaccine. The active substances and other ingredients in Daronrix are listed at the end of the leaflet. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. However, in a pandemic situation, it may be appropriate to give the vaccine, provided that facilities for resuscitation are immediately available in case of need. TAKE SPECIAL CARE WITH DARONRIX: • if you have a severe infection with a high temperature (over 38°C). A minor infection suc Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Daronrix, suspension for injection in pre-filled syringe Pandemic influenza vaccine (whole virion, inactivated, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Whole virion influenza vaccine of pandemic strain, inactivated, containing antigen * equivalent to: _ _ A/Vietnam/1194/2004 (H5N1) *** 15 micrograms ** per 0.5 ml dose * propagated in eggs ** haemagglutinin *** adjuvanted by aluminium phosphate 0.45 milligrams Al 3+ and aluminium hydroxide, hydrated 0.05 milligrams Al 3+ This vaccine complies with the WHO recommendation and EU decision for the pandemic. Excipients: Thiomersal 50 micrograms For a full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Turbid white suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance. (see sections 4.2 and 5.1) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Daronrix has been evaluated with a haemagglutinin content of 15 µg HA per dose in adults aged 18-60 years following a 0, 21 day schedule. Adults from the age of 18 to 60 years will receive two doses of Daronrix, the first administered at an elected date, the second at least three weeks after the first dose for maximum efficacy. No data have been generated with Daronrix below 18 years of age. Therefore health care providers need to assess the benefits and potential risks of administering the vaccine in that population. For pregnant women, see section 4.6. 3 For further information, see section 5.1. Immunisation should be carried out by intramuscular injection. 4.3 CONTRAINDICATIONS History of an anaphylactic reaction (i.e. life-threatening) to any of the constituents or trace residues (e.g. eggs, chicken protein, gentamicin sulphate) of this vaccine. However, in a pandemic situation, it may be appropriate to give the vaccine, provided that facilitie Read the complete document